Kanes Stephen 4

What Happened
Stephen Kanes, Chief Medical Officer of Centessa Pharmaceuticals plc (CNTA), received a grant of 120,000 restricted share units (RSUs) on February 2, 2026. The RSUs were reported as acquired at $0.00 (no cash paid) and represent the contingent right to receive ordinary shares of the company. The award is a compensation grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02 (Form filed 2026-02-03). No late filing indication.
• Instrument and amount: 120,000 RSUs; acquisition price reported $0.00 (value not a cash purchase).
• Vesting: RSUs vest and settle in four equal annual installments; first vesting on February 2, 2027 (per footnote).
• Footnotes: F1 — Ordinary Shares may be represented by American Depositary Shares (each ADS currently represents one Ordinary Share). F2 — RSUs are issued under the company’s 2021 Stock Option and Incentive Plan and convert to shares on vesting.
• Shares owned after transaction: not specified in the filing.
• Remarks/exhibit: Exhibit 24.2 (Substitute Power of Attorney) attached.

Context
RSU grants are a common part of executive compensation and reflect an award that vests over time; they are not an immediate cash outlay or a market buy/sell signal. These RSUs will only convert into actual ordinary shares as they vest over the next four years, so they do not increase tradable shares until settlement.